A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test

International Journal of Infectious Diseases

Yasuhiro Tsuji¹  Yushi Murai²  Hitoshi Kawasuji²  Ippei Sakamaki²  Yuki Miyajima²  Yasutaka Fukui²  Yusuke Takegoshi²  Yoshihiro Yamamoto²  Akitoshi Ueno²  Koyomi Kawago²  Makito Kaneda²  Kou Kimoto²  Chika Ogami³  Yoshitomo Morinaga⁴ 

[1] Center for Pharmacist Education, School of Pharmacy, Nihon University, 3.7-7-1 Narashinodai, Funabashi, Chiba, 274-8555, Japan;Department of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan;Department of Medical Pharmaceutics, Graduate School of Medical and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan;Department of Microbiology, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2.2630 Sugitani, Toyama, 930-0194, Japan;

关键词: COVID-19;    SARS-CoV-2;    Favipiravir;    Drug fever;    Drug-induced lymphocyte stimulation test;   

DOI  :  

来源: DOAJ

【 摘 要 】

As of October 2020, there is still no specific drug to treat COVID-19 as it rages worldwide. Favipiravir, indicated for the treatment of new and re-emerging influenza infections, has been suggested to be effective against SARS-CoV-2, although this is not yet fully validated. We administered favipiravir to a 64-year-old female patient with COVID-19. Her symptoms resolved quickly after the start of treatment, with reduction of SARS-CoV-2 viral load, but she developed a fever again on day 12. Since the fever was relieved by discontinuation of favipiravir, and based on positive results with a drug-induced lymphocyte stimulation test, we diagnosed her with favipiravir-induced drug fever. A decrease in the serum concentration of favipiravir was observed along with resolution of the fever. The present case suggests that drug fever should be considered in the differential diagnosis of relapsing fever episodes in COVID-19 patients receiving favipiravir.

【 授权许可】

Unknown